top of page
surf break copy_edited.jpg

Renibus Therapeutics Announces Appointment of Frank Stonebanks as CEO and $35 Million Series A

Renibus Therapeutics® (“Renibus”), a clinical-stage biotech company focusing on the prevention and treatment of cardiorenal diseases, announced today that Frank Stonebanks has been appointed as Chief Executive Officer, bringing more than 25 years of experience across healthcare and venture capital (VC) to lead Renibus in its next phase of growth. The Company also announced it has completed a $15 million extension as part of of its Series A financing, led by family offices specializing in biotech investments, closing the round at $35 million.

Recent Posts

See All


bottom of page